신장 및 비뇨기과용 의료기기 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별, 최종 용도별, 지역별 및 부문별 예측(2026-2033년)

Nephrology & Urology Devices Market Summary

The global nephrology and urology devices market size was estimated at USD 6.73 billion in 2025 and is projected to reach USD 11.73 billion by 2033, growing at a CAGR of 7.26% from 2026 to 2033. This growth is driven by the rising prevalence of chronic kidney disease, urolithiasis, and urinary system cancers, along with the increasing burden of diabetes and hypertension that contribute to long-term renal complications.

The growing adoption of minimally invasive and endourological procedures, including advanced catheterization, stenting, and stone management techniques, is further accelerating demand for specialized devices. In addition, expanding healthcare infrastructure, improved access to diagnostic and interventional urology services, and continuous innovation in biomaterials and device design are supporting procedural efficiency and patient outcomes. The shift toward outpatient and ambulatory surgical care, combined with increasing awareness of early diagnosis and treatment, is also contributing to sustained market expansion.

The rising prevalence of urological and renal disorders is a primary driver of growth in the nephrology and urology devices market. Conditions such as chronic kidney disease, kidney stones, and benign prostatic hyperplasia are increasing due to aging populations, sedentary lifestyles, diabetes, and hypertension. As these diseases progress, they require continuous clinical management, thereby increasing demand for a wide range of medical devices. For instance, CKD patients progress to end-stage renal disease, necessitating long-term dialysis supported by machines, dialyzers, and vascular access devices.

The growing incidence of kidney stones has led to a greater number of endourological procedures, such as ureteroscopy, which rely heavily on devices such as ureteral catheters, guidewires, and stone retrieval systems. In the case of BPH and other lower urinary tract disorders, increased patient volumes are driving the use of catheters, stents, and minimally invasive treatment devices. In addition, many of these conditions are chronic and recurrent, leading to repeated procedures and long-term device use, which significantly increases overall market demand. This sustained and expanding patient pool translates into higher procedural volumes and continuous consumption of disposable devices, making disease prevalence a key growth engine for the market.

Global Nephrology And Urology Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global nephrology And urology devices market report based on product, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Ureteral Catheters
  • Intermittent Catheters
  • Foley / Indwelling Catheters
  • External Catheters
• PCN Catheters
• Urinary Stents
  • Metallic Ureteral Stents
  • Polymer Ureteral Stents
  • Silicone Stents
  • Polyurethane Stents
  • Hybrid Stents
• Stone Basket
  • Disposable
  • Reusable
• Urology Guidewires
  • Nitinol Guidewires
  • Stainless Steel Guidewires
  • PTFE Guidewires
  • Others
• Renal Dilators
  • Disposable
  • Reusable
• Other
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Urolithiasis
• Urological Cancer & BPH
• Bladder Disorders
• Kidney Diseases
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Clinics
• Ambulatory Surgical Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Third Party Perspective
  • 1.3.5. Primary research
  • 1.3.6. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.1.1. Approach 1: Commodity flow approach
  • 1.6.2. Volume price analysis (Model 2)
    • 1.6.2.1. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. List of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights Outlook

Chapter 3. Nephrology and Urology Devices Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Related/ancillary market outlook.
• 3.2. User Perspective Analysis
  • 3.2.1. Consumer behavior analysis
• 3.3. Market Dynamics
  • 3.3.1. Market driver analysis
    • 3.3.1.1. Rising prevalence of urological and renal disorders
    • 3.3.1.2. Increase in minimally invasive procedures
    • 3.3.1.3. Favorable reimbursement framework
    • 3.3.1.4. Technological advancements
  • 3.3.2. Market restraint analysis
    • 3.3.2.1. Strict reimbursement policies and quantity limits
    • 3.3.2.2. Pricing pressure
    • 3.3.2.3. Risk of infections and complications
  • 3.3.3. Market opportunities analysis
    • 3.3.3.1. Expansion of home healthcare segment and remote patient monitoring
    • 3.3.3.2. Innovation in minimally invasive therapies
    • 3.3.3.3. Untapped potential in female urology devices
    • 3.3.3.4. Emerging technologies in robotic urology and smart drainage systems
  • 3.3.4. Market challenges analysis
    • 3.3.4.1. Supply chain disruptions
    • 3.3.4.2. Training requirements for advanced urology and dialysis devices
    • 3.3.4.3. Competition from low-cost alternatives and commoditization of consumables
• 3.4. Nephrology and Urology Devices Market Analysis Tools
  • 3.4.1. Industry Analysis - Porter's
    • 3.4.1.1. Supplier power
    • 3.4.1.2. Buyer power
    • 3.4.1.3. Substitution threat
    • 3.4.1.4. Threat of new entrant
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Technological landscape
    • 3.4.2.3. Economic landscape

Chapter 4. Nephrology and Urology Devices Market: Product Estimates & Trend Analysis

• 4.1. Definitions and Scope
• 4.2. Product Market Share, 2021 & 2033
• 4.3. Segment Dashboard
• 4.4. Global Nephrology & Urology Devices Market by Product Outlook
• 4.5. Market Size & Forecasts and Trend Analyses, 2025 to 2033 for the following
  • 4.5.1. Ureteral Catheters
    • 4.5.1.1. Ureteral catheters market estimates and forecast 2021 to 2033 (USD Million, Volume Unit)
    • 4.5.1.2. Intermittent Catheters
    • 4.5.1.3. Foley/ Indwelling Catheters
    • 4.5.1.4. External Catheters
  • 4.5.2. PCN Catheters
    • 4.5.2.1. PCN catheters market estimates and forecast 2021 to 2033 (USD Million, Volume Unit)
  • 4.5.3. Urinary Stents
    • 4.5.3.1. Urinary stents market estimates and forecast 2021 to 2033 (USD Million, Volume Unit)
    • 4.5.3.2. Metallic Ureteral Stents
    • 4.5.3.3. Polymer Ureteral Stents
      • 4.5.3.3.1. Silicone Stents
      • 4.5.3.3.2. Polyurethane Stents
      • 4.5.3.3.3. Hybrid Stents
  • 4.5.4. Stone Basket
    • 4.5.4.1. Stone basket market estimates and forecast 2021 to 2033 (USD Million, Volume Unit)
    • 4.5.4.2. Disposable
    • 4.5.4.3. Reusable
  • 4.5.5. Urology Guidewires
    • 4.5.5.1. Urology guidewires market estimates and forecast 2021 to 2033 (USD Million, Volume Unit)
    • 4.5.5.2. Nitinol Guidewires
    • 4.5.5.3. Stainless Steel Guidewires
    • 4.5.5.4. PTEE Guidewires
    • 4.5.5.5. Others
  • 4.5.6. Renal Dilators
    • 4.5.6.1. Renal dilators market estimates and forecast 2021 to 2033 (USD Million, Volume Unit)
    • 4.5.6.2. Disposable
    • 4.5.6.3. Reusable
  • 4.5.7. Other
    • 4.5.7.1. Other market estimates and forecast 2021 to 2033 (USD Million, Volume Unit)

Chapter 5. Nephrology & Urology Devices Market: Application Estimates & Trend Analysis

• 5.1. Definitions and Scope
• 5.2. Application Market Share, 2021 & 2033
• 5.3. Segment Dashboard
• 5.4. Global Nephrology & Urology Devices Market by Application Outlook
• 5.5. Market Size & Forecasts and Trend Analyses, 2025 to 2033 for the following
  • 5.5.1. Urolithiasis
    • 5.5.1.1. Urolithiasis market estimates and forecast 2021 to 2033 (USD Million)
  • 5.5.2. Urological Cancer & BPH
    • 5.5.2.1. Urological cancer & BPH market estimates and forecast 2021 to 2033 (USD Million)
  • 5.5.3. Bladder Disorders
    • 5.5.3.1. Bladder disorders market estimates and forecast 2021 to 2033 (USD Million)
  • 5.5.4. Kidney Diseases
    • 5.5.4.1. Kidney diseases market estimates and forecast 2021 to 2033 (USD Million)
  • 5.5.5. Other
    • 5.5.5.1. Other market estimates and forecast 2021 to 2033 (USD Million)

Chapter 6. Nephrology & Urology Devices Market: End Use Estimates & Trend Analysis

• 6.1. Definitions and Scope
• 6.2. End Use Market Share, 2021 & 2033
• 6.3. Segment Dashboard
• 6.4. Global Nephrology & Urology Devices Market by End Use Outlook
• 6.5. Market Size & Forecasts and Trend Analyses, 2025 to 2033 for the following
  • 6.5.1. Hospitals
    • 6.5.1.1. Hospitals market estimates and forecast 2021 to 2033 (USD Million)
  • 6.5.2. Clinics
    • 6.5.2.1. Clinics market estimates and forecast 2021 to 2033 (USD Million)
  • 6.5.3. Ambulatory Surgical Centers
    • 6.5.3.1. Ambulatory Surgical Centers market estimates and forecast 2021 to 2033 (USD Million)
  • 6.5.4. Other
    • 6.5.4.1. Other market estimates and forecast 2021 to 2033 (USD Million)

Chapter 7. Nephrology & Urology Devices Market: Regional Estimates & Trend Analysis by Product, Application, End Use

• 7.1. Regional market share analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Regional Market Share and Leading Players, 2025
• 7.5. Market Application, & Forecasts and Trend Analysis, 2021 to 2033:
• 7.6. North America
  • 7.6.1. Market estimates and forecast, 2021 - 2033 (Revenue, USD Million)
  • 7.6.2. U.S.
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Competitive scenario
    • 7.6.2.3. Regulatory framework
    • 7.6.2.4. Reimbursement scenario
    • 7.6.2.5. U.S. market estimates and forecasts, 2021 - 2033
  • 7.6.3. Canada
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Competitive scenario
    • 7.6.3.3. Regulatory framework
    • 7.6.3.4. Reimbursement scenario
    • 7.6.3.5. Canada market estimates and forecasts, 2021 - 2033
  • 7.6.4. Mexico
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Competitive scenario
    • 7.6.4.3. Regulatory framework
    • 7.6.4.4. Reimbursement scenario
    • 7.6.4.5. Mexico market estimates and forecasts, 2021 - 2033
• 7.7. Europe
  • 7.7.1. Germany
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Competitive scenario
    • 7.7.1.3. Regulatory framework
    • 7.7.1.4. Reimbursement scenario
    • 7.7.1.5. Germany market estimates and forecasts, 2021 - 2033
  • 7.7.2. UK
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Competitive scenario
    • 7.7.2.3. Regulatory framework
    • 7.7.2.4. Reimbursement scenario
    • 7.7.2.5. UK market estimates and forecasts, 2021 - 2033
  • 7.7.3. France
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Competitive scenario
    • 7.7.3.3. Regulatory framework
    • 7.7.3.4. Reimbursement scenario
    • 7.7.3.5. France market estimates and forecasts, 2021 - 2033
  • 7.7.4. Italy
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Competitive scenario
    • 7.7.4.3. Regulatory framework
    • 7.7.4.4. Reimbursement scenario
    • 7.7.4.5. Italy market estimates and forecasts, 2021 - 2033
  • 7.7.5. Spain
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Competitive scenario
    • 7.7.5.3. Regulatory framework
    • 7.7.5.4. Reimbursement scenario
    • 7.7.5.5. Spain market estimates and forecasts, 2021 - 2033
  • 7.7.6. Denmark
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Competitive scenario
    • 7.7.6.3. Regulatory framework
    • 7.7.6.4. Reimbursement scenario
    • 7.7.6.5. Denmark market estimates and forecasts, 2021 - 2033
  • 7.7.7. Sweden
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Competitive scenario
    • 7.7.7.3. Regulatory framework
    • 7.7.7.4. Reimbursement scenario
    • 7.7.7.5. Sweden market estimates and forecasts, 2021 - 2033
  • 7.7.8. Norway
    • 7.7.8.1. Key country dynamics
    • 7.7.8.2. Competitive scenario
    • 7.7.8.3. Regulatory framework
    • 7.7.8.4. Reimbursement scenario
    • 7.7.8.5. Norway market estimates and forecasts, 2021 - 2033
• 7.8. Asia Pacific
  • 7.8.1. China
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Competitive scenario
    • 7.8.1.3. Regulatory framework
    • 7.8.1.4. Reimbursement scenario
    • 7.8.1.5. China market estimates and forecasts, 2021 - 2033
  • 7.8.2. Japan
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Competitive scenario
    • 7.8.2.3. Regulatory framework
    • 7.8.2.4. Reimbursement scenario
    • 7.8.2.5. Japan market estimates and forecasts, 2021 - 2033
  • 7.8.3. India
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Competitive scenario
    • 7.8.3.3. Regulatory framework
    • 7.8.3.4. Reimbursement scenario
    • 7.8.3.5. India market estimates and forecasts, 2021 - 2033
  • 7.8.4. Australia
    • 7.8.4.1. Key country dynamics
    • 7.8.4.2. Competitive scenario
    • 7.8.4.3. Regulatory framework
    • 7.8.4.4. Reimbursement scenario
    • 7.8.4.5. Australia market estimates and forecasts, 2021 - 2033
  • 7.8.5. South Korea
    • 7.8.5.1. Key country dynamics
    • 7.8.5.2. Competitive scenario
    • 7.8.5.3. Regulatory framework
    • 7.8.5.4. Reimbursement scenario
    • 7.8.5.5. South Korea market estimates and forecasts, 2021 - 2033
  • 7.8.6. Thailand
    • 7.8.6.1. Key country dynamics
    • 7.8.6.2. Competitive scenario
    • 7.8.6.3. Regulatory framework
    • 7.8.6.4. Reimbursement scenario
    • 7.8.6.5. Thailand market estimates and forecasts, 2021 - 2033
• 7.9. Latin America
  • 7.9.1. Brazil
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Competitive scenario
    • 7.9.1.3. Regulatory framework
    • 7.9.1.4. Reimbursement scenario
    • 7.9.1.5. Brazil market estimates and forecasts, 2021 - 2033
  • 7.9.2. Argentina
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Competitive scenario
    • 7.9.2.3. Regulatory framework
    • 7.9.2.4. Reimbursement scenario
    • 7.9.2.5. Argentina market estimates and forecasts, 2021 - 2033
• 7.10. MEA
  • 7.10.1. South Africa
    • 7.10.1.1. Key country dynamics
    • 7.10.1.2. Competitive scenario
    • 7.10.1.3. Regulatory framework
    • 7.10.1.4. Reimbursement scenario
    • 7.10.1.5. South Africa market estimates and forecasts, 2021 - 2033
  • 7.10.2. Saudi Arabia
    • 7.10.2.1. Key country dynamics
    • 7.10.2.2. Competitive scenario
    • 7.10.2.3. Regulatory framework
    • 7.10.2.4. Reimbursement scenario
    • 7.10.2.5. Saudi Arabia market estimates and forecasts, 2021 - 2033
  • 7.10.3. UAE
    • 7.10.3.1. Key country dynamics
    • 7.10.3.2. Competitive scenario
    • 7.10.3.3. Regulatory framework
    • 7.10.3.4. Reimbursement scenario
    • 7.10.3.5. UAE market estimates and forecasts, 2021 - 2033
  • 7.10.4. Kuwait
    • 7.10.4.1. Key country dynamics
    • 7.10.4.2. Competitive scenario
    • 7.10.4.3. Regulatory framework
    • 7.10.4.4. Reimbursement scenario
    • 7.10.4.5. Kuwait market estimates and forecasts, 2021 - 2033

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
  • 8.2.1. Innovators
• 8.3. List of Distributors
• 8.4. Vendor Landscape
  • 8.4.1. List of key distributors and channel partners
  • 8.4.2. Key customers
  • 8.4.3. Region wise key company market share analysis, 2025
  • 8.4.4. Hollister Incorporated
    • 8.4.4.1. Company overview
    • 8.4.4.2. Financial performance
    • 8.4.4.3. Product benchmarking
    • 8.4.4.4. Strategic initiatives
  • 8.4.5. Coloplast
    • 8.4.5.1. Company overview
    • 8.4.5.2. Financial performance
    • 8.4.5.3. Product benchmarking
    • 8.4.5.4. Strategic initiatives
  • 8.4.6. Boston Scientific Corporation
    • 8.4.6.1. Company overview
    • 8.4.6.2. Financial performance
    • 8.4.6.3. Product benchmarking
    • 8.4.6.4. Strategic initiatives
  • 8.4.7. B. Braun SE
    • 8.4.7.1. Company overview
    • 8.4.7.2. Financial performance
    • 8.4.7.3. Product benchmarking
    • 8.4.7.4. Strategic initiatives
  • 8.4.8. Teleflex Incorporated
    • 8.4.8.1. Company overview
    • 8.4.8.2. Financial performance
    • 8.4.8.3. Product benchmarking
    • 8.4.8.4. Strategic initiatives
  • 8.4.9. Baxter
    • 8.4.9.1. Company overview
    • 8.4.9.2. Financial performance
    • 8.4.9.3. Product benchmarking
    • 8.4.9.4. Strategic initiatives
  • 8.4.10. Fresenius Medical Care AG & Co.
    • 8.4.10.1. Company overview
    • 8.4.10.2. Financial performance
    • 8.4.10.3. Product benchmarking
    • 8.4.10.4. Strategic initiatives
  • 8.4.11. Asahi Kasei Corporation
    • 8.4.11.1. Company overview
    • 8.4.11.2. Financial performance
    • 8.4.11.3. Product benchmarking
    • 8.4.11.4. Strategic initiatives
  • 8.4.12. Cook Group
    • 8.4.12.1. Company overview
    • 8.4.12.2. Financial performance
    • 8.4.12.3. Product benchmarking
    • 8.4.12.4. Strategic initiatives
  • 8.4.13. Terumo Corporation
    • 8.4.13.1. Company overview
    • 8.4.13.2. Financial performance
    • 8.4.13.3. Product benchmarking
    • 8.4.13.4. Strategic initiatives
  • 8.4.14. Nipro Medical Corporation
    • 8.4.14.1. Company overview
    • 8.4.14.2. Financial performance
    • 8.4.14.3. Product benchmarking
    • 8.4.14.4. Strategic initiatives
  • 8.4.15. BD
    • 8.4.15.1. Company overview
    • 8.4.15.2. Financial performance
    • 8.4.15.3. Product benchmarking
    • 8.4.15.4. Strategic initiatives
  • 8.4.16. Olympus
    • 8.4.16.1. Company overview
    • 8.4.16.2. Financial performance
    • 8.4.16.3. Product benchmarking
    • 8.4.16.4. Strategic initiatives
  • 8.4.17. Allium Medical
    • 8.4.17.1. Company overview
    • 8.4.17.2. Financial performance
    • 8.4.17.3. Product benchmarking
    • 8.4.17.4. Strategic initiatives
  • 8.4.18. Pnn Medical A/S
    • 8.4.18.1. Company overview
    • 8.4.18.2. Financial performance
    • 8.4.18.3. Product benchmarking
    • 8.4.18.4. Strategic initiatives
  • 8.4.19. Merit Medical Systems (BioLife Plasma Services)
    • 8.4.19.1. Company overview
    • 8.4.19.2. Financial performance
    • 8.4.19.3. Product benchmarking
    • 8.4.19.4. Strategic initiatives
  • 8.4.20. Convatec
    • 8.4.20.1. Company overview
    • 8.4.20.2. Financial performance
    • 8.4.20.3. Product benchmarking
    • 8.4.20.4. Strategic initiatives
  • 8.4.21. Ur24Technology, Inc.
    • 8.4.21.1. Company overview
    • 8.4.21.2. Financial performance
    • 8.4.21.3. Product benchmarking
    • 8.4.21.4. Strategic initiatives
  • 8.4.22. Sterimed Group
    • 8.4.22.1. Company overview
    • 8.4.22.2. Financial performance
    • 8.4.22.3. Product benchmarking
    • 8.4.22.4. Strategic initiatives
  • 8.4.23. Wellspect HealthCare, a Dentsply Sirona Company
    • 8.4.23.1. Company overview
    • 8.4.23.2. Financial performance
    • 8.4.23.3. Product benchmarking
    • 8.4.23.4. Strategic initiatives
  • 8.4.24. Boehringer Laboratories, LLC
    • 8.4.24.1. Company overview
    • 8.4.24.2. Financial performance
    • 8.4.24.3. Product benchmarking
    • 8.4.24.4. Strategic initiatives
  • 8.4.25. Medline Industries, LP.
    • 8.4.25.1. Company overview
    • 8.4.25.2. Financial performance
    • 8.4.25.3. Product benchmarking
    • 8.4.25.4. Strategic initiatives